Lessons from the COMPASS-3 Study

por Shah, Trushil, Chin, Kelly M
Publicado 2018

Outcomes After Supraventricular Tachycardia Ablation in Patients With Group 1 Pulmonary Hypertension

por Satish, Tejus, Chin, Kelly, Patel, Nimesh
Publicado 2023

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

por Hardin, Elizabeth Ashley, Chin, Kelly M
Publicado 2016

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

por Sodimu, Adetoun, Bartolome, Sonja, Igenoza, Oluwatosin P., Chin, Kelly M.
Publicado 2020

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag

por Hinkamp, Colin, Bartolome, Sonja, Mims, Edward, Chin, Kelly, Shah, Trushil
Publicado 2022

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

por Frantz, Robert P., Chin, Kelly M., Zhao, Carol, Flynn, Megan, Badesch, David
Publicado 2020

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction

por Hinkamp, Colin A., Shah, Trushil, Bartolome, Sonja, Torres, Fernando, Chin, Kelly M.
Publicado 2021

Arterial thromboembolic complications in COVID‐19 in low‐risk patients despite prophylaxis

por Griffin, Daniel O., Jensen, Alexandra, Khan, Mushmoom, Chin, Jessica, Chin, Kelly, Parnell, Ryan, Awwad, Christopher, Patel, Darshan
Publicado 2020

Remote Advance Care Planning in the Emergency Department During COVID-19 Disaster: Program Development and Initial Evaluation

por Liberman, Tara, Roofeh, Regina, Chin, Jessica, Chin, Kelly, Razack, Bibi, Aquilino, Joseph, Herod, Sarah Healey, Amato, Teresa
Publicado 2022

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

por Abu‐Rmaileh, Muhammad, Mirza, Omer, Patel, Chandni, Shah, Trushil, Hardin, Elizabeth A., Bartolome, Sonja D., Chin, Kelly M.
Publicado 2023

Pulmonary Embolism and Increased Levels of D-Dimer in Patients with Coronavirus Disease

por Griffin, Daniel O., Jensen, Alexandra, Khan, Mushmoom, Chin, Jessica, Chin, Kelly, Saad, Jennifer, Parnell, Ryan, Awwad, Christopher, Patel, Darshan
Publicado 2020

Cytokine storm of a different flavour: The different cytokine signature of SARS-CoV-2, the cause of COVID-19, from the original SARS outbreak

por Griffin, Daniel O., Jensen, Alexandra, Khan, Mushmoom, Chin, Jessica, Chin, Kelly, Saad, Jennifer, Parnell, Ryan, Awwad, Christopher, Patel, Darshan
Publicado 2021

Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update

por Vonk Noordegraaf, Anton, Chin, Kelly Marie, Haddad, François, Hassoun, Paul M., Hemnes, Anna R., Hopkins, Susan Roberta, Kawut, Steven Mark, Langleben, David, Lumens, Joost, Naeije, Robert
Publicado 2019

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, pha...

por Klose, Hans, Chin, Kelly M., Ewert, Ralf, Gall, Henning, Parambil, Joseph, Poch, David, Seyfarth, Hans-Jürgen, Axelsen, Lene N., Hsu Schmitz, Shu-Fang, Stein, Claudia, Preston, Ioana R.
Publicado 2021

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

por McLaughlin, Vallerie V., Channick, Richard, Kim, Nick H., Frantz, Robert P., McConnell, John W., Melendres‐Groves, Lana, Miller, Chad, Ravichandran, Ashwin, Rodriguez‐Lopez, Josanna, Brand, Monika, Leroy, Sandrine, Wetherill, Graham, Chin, Kelly M.
Publicado 2022

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

por Galiè, Nazzareno, Gaine, Sean, Channick, Richard, Coghlan, J. Gerry, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Lassen, Cheryl, Rubin, Lewis J., Hsu Schmitz, Shu-Fang, Sitbon, Olivier, Tapson, Victor F., Chin, Kelly M.
Publicado 2021

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

por Rosenkranz, Stephan, Channick, Richard, Chin, Kelly M., Jenner, Bartosz, Gaine, Sean, Galiè, Nazzareno, Ghofrani, Hossein‐Ardeschir, Hoeper, Marius M., McLaughlin, Vallerie V., Du Roure, Camille, Rubin, Lewis J., Sitbon, Olivier, Tapson, Victor, Lang, Irene M.
Publicado 2021

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

por Gaine, Sean, Chin, Kelly, Coghlan, Gerry, Channick, Richard, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Lang, Irene M., McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Hoeper, Marius M.
Publicado 2017

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

por Chin, Kelly M., Rubin, Lewis J., Channick, Richard, Di Scala, Lilla, Gaine, Sean, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Preiss, Ralph, Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F.
Publicado 2019

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRI...

por Coghlan, J. Gerry, Channick, Richard, Chin, Kelly, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Gaine, Sean
Publicado 2018